Abivax S.A.

Abivax S.A. American Depositary Receipt represents shares in Abivax SA, a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms, particularly through enhanced expression of microRNA-124, to stabilize the immune response in patients with chronic inflammatory diseases. The company's lead drug candidate, obefazimod, is an oral, once-daily small molecule in Phase 3 clinical trials under the ABTECT program for adults with moderately to severely active ulcerative colitis, with positive top-line results from 8-week induction trials announced in Q3 2025 and maintenance data anticipated in Q2 2026. Obefazimod is also advancing in a Phase 2b trial, ENHANCE-CD, for Crohn's disease, with patient enrollment initiated in Q3 2024 and induction data expected in Q4 2026. Additional efforts include evaluating obefazimod in combination therapies for ulcerative colitis and exploring its potential in other inflammatory indications, alongside research into follow-on compounds from a proprietary chemical library. Abivax conducts its research and development primarily at its center in Montpellier, France, in collaboration with institutions like CNRS and the University of Montpellier. Incorporated in 2013 and headquartered in Paris, France, with a US office in Waltham, Massachusetts, Abivax plays a significant role in advancing treatments for inflammatory bowel diseases within the biotechnology sector.